Oncology Institute Inc. (TOI)
| Bid | 2.14 |
| Market Cap | 164.76M |
| Revenue (ttm) | 393.41M |
| Net Income (ttm) | -61.05M |
| EPS (ttm) | -0.71 |
| PE Ratio (ttm) | -3.06 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 2.31 |
| Volume | 903,181 |
| Avg. Volume (20D) | 922,346.1 |
| Open | 1.94 |
| Previous Close | 1.94 |
| Day's Range | 1.91 - 2.26 |
| 52-Week Range | 0.13 - 2.35 |
| Beta | 0.24 |
About TOI
The Oncology Institute, Inc., an oncology company, provides medical oncology services in the United States. Its services include physician services, in-house infusion and dispensary, clinical trial services, radiation, outpatient stem cell transplants and transfusions programs, and patient support. The company also offers and manages clinical trial services, such as managing clinical trials, palliative care programs, and stem cell transplants ser...
Analyst Forecast
According to 1 analyst ratings, the average rating for TOI stock is "Buy." The 12-month stock price forecast is $2.5, which is an increase of 14.94% from the latest price.
Stock Forecasts
3 weeks ago · seekingalpha.com
The Oncology Institute, Inc. (TOI) Q4 2024 Earnings Call TranscriptThe Oncology Institute, Inc. (NASDAQ:TOI ) Q4 2024 Earnings Conference Call March 25, 2025 5:00 PM ET Company Participants Mark Hueppelsheuser - General Counsel Daniel Virnich - CEO Rob Carter - CFO C...